Background: Primary bone tumors are extremely rare neoplasm, accounting for less than 0.2% of all tumors but mortality related to them is disproportionately high, especially among teenagers and young adults. Oxidative stress plays a major role in the pathogenesis of bone tumors. Nitric oxide (NO) is a well proven marker of oxidative stress and in recent years, Ischemia Modified Albumin (IMA) has also emerged as a new biomarker in some cancers. Hence, this study was planned to determine the role of oxidative stress in primary bone tumor patients by measuring NO and IMA levels together, before and after treatment.
Methods: A total of 98 subjects were included in the study. Out of these, 50 were healthy controls and 48 were histopathologically proven patients of bone tumors. Out of 48, 14 were benign and 34 were malignant tumors. The NO level [measured as nitrite-plus-nitrate {NO(x)} concentration] and IMA were estimated before (group I) and 2 weeks after standard treatment. Data was compared among different groups using appropriate statistical analysis.
Results: The levels of NO and IMA were found to be statistically significantly higher in cases than controls (p<0.05). The levels were significantly more in patients with malignant tumor as compared to benign tumor (p<0.01). A strong positive correlation (r=0.84; p<0.01) was found between IMA and NO in cases.
Conclusions: Increased levels of IMA and NO strongly favor the increased oxidative stress in primary bone tumor patients and may act as potential biomarkers for diagnosis and prognosis.
Impact Factor
2022: 6.012
This work is licensed under a